Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

5 ML zoledronic acid 0.8 MG/ML Injection [Zometa]

Known as: Zometa 4 MG in 5 ML Injection, 5 ML Zometa 0.8 MG/ML Injection, Zometa 4 MG per 5 ML Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa®, ZA), routinely used to treat… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Highly Cited
2012
Highly Cited
2012
BACKGROUND The extracellular matrix (ECM) components play key roles in the multistep process of cancer growth and progression… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
SummaryAbstractZoledronic acid (Zometa®1) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
2012
2012
SummaryAbstractZoledronic acid (Zometa®), a third-generation amino-bisphosphonate, has been approved in the US, the EU and many… Expand
  • table I
  • table II
  • table III
  • table IV
  • table V
2009
2009
Bisphosphonates are widely used as therapeutic agents in bone disorders including cancer metastasis due to their osteoclast… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2006
2006
Zoledronic acid (ZA; Zometa®) is a cyclic nitrogen-containing bisphosphonate with anti-tumor activity used to treat patients with… Expand
Highly Cited
2004
Highly Cited
2004
Pamidronate (PAM) and zoledronic acid (ZOL) are aminobisphosphonates (BPs) able to affect the isoprenylation of intracellular… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2003
2003
AbstractZoledronic acid (Zometa®) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid demonstrated… Expand
2003
2003
Summary This report summarises the results of the clinical development program of zoledronic acid (Zometa ® ), a third generation… Expand
2000
2000
Metastatic bone disease develops as a result of the many interactions between tumour cells and bone cells. This leads to… Expand